FDA Developing Brand/Generic Labeling “Carve Out” Notification Process
Executive Summary
FDA is developing a process to inform innovators and generic companies when part of a brand drug's labeling can be "carved out" of an ANDA, Associate Counsel for Drugs Elizabeth Dickinson said
You may also be interested in...
Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma
Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17
Method Of Use Patents Gaining Greater Importance In The Eyes Of Pharma
Large pharmaceutical manufacturers are beginning to see method of use patents as a more valuable piece of their patent portfolios, Gene Logic CEO Mark Gessler said at the Biotechnology Industry Organization/Windhover Partnering Conference for Decision Makers in Washington, D.C. May 17
Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect
The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations